Vistagen Therapeutics, Inc. current report, 07 October 2026

Vistagen Therapeutics, Inc. — Form 8-K Summary

Reporting context: The 8-K reports an event dated October 7, 2026, and was signed October 9, 2026. Vistagen is a Nevada corporation whose common stock trades on the Nasdaq Capital Market under VTGN.

Material event

On October 7, 2026, the Board approved an amendment and restatement of the Company’s Change in Control Executive Severance Plan, effective that date. The plan was originally adopted effective August 11, 2026.

  • The revised plan generally defines a Qualifying Termination as termination by the Company without Cause, or by an eligible employee for Good Reason during the period beginning three months before and ending 18 months after a Change in Control.
  • Unlike the original plan, the revised plan can provide severance for an eligible employee terminated without Cause whether or not a Change in Control occurs.
  • For qualifying terminations not connected to a Change in Control, benefits generally include a lump-sum payment based on monthly base salary and the applicable severance period, plus a lump-sum payment based on applicable COBRA premiums and the benefits continuation period if coverage is timely elected.
  • Benefits are subject to timely execution and non-revocation of a release of claims. Eligibility generally requires at least 12 months of full-time employment. All current executive officers are eligible under the revised plan.
  • The plan also revises the definition of Change in Control by specifying the relevant transactions directly in the plan.

Financial metrics and outlook

This 8-K does not report revenue, profit, cash flow, margins, debt, liquidity, or financial guidance. It provides no clear monetary estimate of potential severance costs.

Investor verification points

  • Review Exhibit 10.1 for the full plan terms, including applicable severance periods, COBRA continuation periods, and defined terms.
  • Assess the potential financial impact of expanded severance eligibility; this filing does not quantify that impact.
  • Confirm how the plan’s eligibility, release, and termination conditions apply to specific employees or circumstances.